Zeuzem, S.

genotype patient steatosi treatment hepatitis decline hepatitis c phase study response allele model virus baseline liver il 28b polymorphisms signi therapy infection hepatology level fi rst phase journal hepatology 2011 vol polymorphism kinetic brosi association group il 28b ficant hepatitis c virus outcome ribavirin body mass index genotype 3 hcv rna hcv infection treatment outcome effect 0.5 fi brosis stage table hcv rna decline rs 12979860 liver steatosis carrier 0.1 phase decline rs 8099917 signi ficantly t carriers vs fi rst day <0.001 p values additive model diplotype rs 12980275 fi brosis 0.4 0.8 value university t allele ditto study -3 group genotype 3 patients kg /m baseline hepatitis c patients g carriers vs genotype 3 group signi ficant 0.72 serum 0.6 0.2 0.04 ficantly analysis genotype 1-